Which has the lower trailing P/E, ALNY or MDLN?

ALNY has the lower trailing P/E: ALNY trades at 40.05 and MDLN at 41.02. P/E is one valuation measure and does not by itself establish which business is cheaper.

Is ALNY or MDLN more profitable?

ALNY runs the higher net margin — ALNY at 16.82% versus MDLN at 2.31%.

Alnylam Pharmaceuticals, Inc. (ALNY) vs Medline Inc. (MDLN)

A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and Medline Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 29, 2026. Differences are shown without an overall score or investment verdict.

ALNY

Alnylam Pharmaceuticals, Inc.

$31.73B

$237.10HealthcareAt close: Aug 28, 2026, 4:00 PM ET

MDLN

Medline Inc.

$29.83B

$35.28HealthcareAt close: Aug 28, 2026, 4:00 PM ET

Total return — ALNY vs MDLN

growth of $100 · dividends reinvested · last 1y

ALNY -41.4% (-41.4%/yr)MDLN -14.0% (-14.0%/yr)MDLN compounded faster over this window

ALNY MDLN

ALNY vs MDLN: by the numbers

•ALNY is the larger company ($31.73B vs $29.83B market cap).
•ALNY trades at the lower trailing earnings multiple (40.05 vs 41.02 P/E), one valuation lens rather than an overall verdict.
•ALNY converts more revenue to profit (16.82% vs 2.31% net margin).

Metrics side by side

Valuation

Metric	ALNY	MDLN
P/E ratio	40.05	41.02
Forward P/E	36.43	23.38
P/S ratio	6.82	1.01
P/B ratio	24.21	2.62
EV / EBITDA	30.68	14.77
FCF yield	1.66%	6.67%

Profitability

Metric	ALNY	MDLN
Gross margin	79.72%	25.02%
Operating margin	20.81%	6.07%
Net margin	16.82%	2.31%
ROE	59.67%	5.97%
ROIC	24.71%	4.05%

Growth (annualized)

Metric	ALNY	MDLN
Revenue CAGR (5Y)	47.53%	N/A
Total return CAGR (5Y)	3.06%	N/A

Frequently asked

Which has the lower trailing P/E, ALNY or MDLN?: ALNY has the lower trailing P/E: ALNY trades at 40.05 and MDLN at 41.02. P/E is one valuation measure and does not by itself establish which business is cheaper.
Is ALNY or MDLN more profitable?: ALNY runs the higher net margin — ALNY at 16.82% versus MDLN at 2.31%.

Go deeper

Full ALNY analysis Full MDLN analysis Interactive comparison tool

Dig into the metrics

Alnylam Pharmaceuticals P/E ratio Medline P/E ratio Alnylam Pharmaceuticals ROE Medline ROE Alnylam Pharmaceuticals operating margin Medline operating margin Alnylam Pharmaceuticals revenue growth Medline revenue growth Alnylam Pharmaceuticals free cash flow Medline free cash flow

Alnylam Pharmaceuticals & Medline appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 29, 2026.